TrialsgrambetaRCTs are beautiful

ASCEND

2014

Pirfenidone in Idiopathic Pulmonary Fibrosis

In 555 patients with IPF (FVC 50–90% predicted), pirfenidone 2,403 mg/day reduced ≥10% FVC decline or death at 52 weeks compared with placebo.

Result

≥10% FVC decline or death at 52 weeks
Absolute difference
15.3 points
Effect estimate

relative reduction47.9

The absolute difference is derived from the event rates.

Also reported: Pooled with CAPACITY, all-cause mortality HR 0.52.

Original publication
Subtopic
Antifibrotic: IPF
Design
Multicentre RCT
Relevance
Practice-defining: a trial the guidelines cite as evidence.
Source
King TE Jr, et al. N Engl J Med. 2014;370(22):2083-2092.doi 10.1056/NEJMoa1402582

Discussion & critique

Together with CAPACITY, supported FDA approval of pirfenidone.